ArticleEye (London, England)2026
10-year analysis of microbiological profiles and in vitro antimicrobial susceptibility: the Kent microbial keratitis study.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the incidence, microbiological profile, and in vitro antimicrobial susceptibility patterns of microbial keratitis (MK) in Kent over a 10-year period.
methodsA retrospective analysis was conducted of all corneal scrape specimens processed between January 2015 and August 2024 at Maidstone and Tunbridge Wells NHS Trust and East Kent Hospitals University NHS Foundation Trust. Data extracted included patient demographics, isolates, and antimicrobial sensitivities. The study period was divided into two time periods (2015-2019 and 2020-2024) for trend analyses.
resultsThe estimated mean incidence of MK was 2.2 per 100,000 population per year. Of 1029 scrapes, 384 were culture-positive (37.3%). Gram-negative organisms predominated (50.9%), followed by Gram-positive (37.8%), fungi (5.0%), and Acanthamoeba (6.3%). Polymicrobial infections accounted for 10.4% of cases. Pseudomonas spp (35.9%), Coagulase-negative Staphylococci (15.0%), and Staphylococcus aureus (9.8%) were most commonly isolated. Average susceptibility of Gram-positive organisms to chloramphenicol, fluoroquinolones, and gentamicin was 96.7%, 76.0% and 92.1%, respectively, and for Gram-negative organisms was 48.2%, 93.4%, and 99.3%, respectively. Concerning trends included a 16.9% reduction in fluoroquinolone susceptibility among Gram-positive isolates (p < 0.001), with moxifloxacin efficacy decreasing by 57.9% (p = 0.002). The prevalence of Acanthamoeba represents an unrecognised regional disease burden, exceeding other UK regions (1.1-4.8%). DISCUSSION: This study identified a marked decline in fluoroquinolone susceptibility among Gram-positive organisms and a significantly higher acanthamoeba prevalence compared to other UK regions and global reports. These findings highlight the importance of ongoing antimicrobial stewardship and support re-evaluation of empiric treatment protocols for MK in Kent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.